For Healthcare Professionals

This clinical trial for relapsed/refractory epNECs is sponsored by Boehringer Ingelheim and is currently enrolling patients. Participating sites with their contact details are mentioned in the table below.

Hospital NameLocationContact NumberEmail Address

UNIV UZ Gent

Gent, Belgium, 9000

80049616

belgique@bitrialsupport.com

UZ Leuven

Leuven, Belgium, 3000

80049616

belgique@bitrialsupport.com

Hospital NameLocationContact NumberEmail Address

West China Hospital

Chengdu, China, 610041

4001200553

china@bitrialsupport.com

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, China, 310016

4001200553

china@bitrialsupport.com

Qilu Hospital, Shangdong University

Jinan, China, 250012

4001200553

china@bitrialsupport.com

960 Hospital of the Chinese People's Liberation Army

Jinan, China, 250031

4001200553

china@bitrialsupport.com

The Second Affiliated Hospital to Nanchang University

Nanchang, China, 330006

4001200553

china@bitrialsupport.com

Not yet recruiting in Part 2

Hospital NameLocationContact NumberEmail Address

National Cancer Center Hospital East

Chiba, Kashiwa, Japan, 277-8577

120201230

nippon@bitrialsupport.com

Kindai University Hospital

Osaka, OsakaSayama, Japan, 589-8511

120201230

nippon@bitrialsupport.com

Osaka International Cancer Institute

Osaka, Osaka, Japan, 541-8567

120201230

nippon@bitrialsupport.com

National Cancer Center Hospital

Tokyo, Chuo-ku, Japan, 104-0045

120201230

nippon@bitrialsupport.com

Japanese Foundation for Cancer Research

Tokyo, Koto-ku, Japan, 135-8550

120201230

nippon@bitrialsupport.com

Hospital NameLocationContact NumberEmail Address

Severance Hospital

Seoul, Korea, Republic of, 03722

808802084

namhan@bitrialsupport.com

Samsung Medical Center

Seoul, Korea, Republic of, 06351

808802084

namhan@bitrialsupport.com

Not yet recruiting in Part 2

Hospital NameLocationContact NumberEmail Address

Leicester Royal Infirmary

Leicester, United Kingdom, LE1 5WW

8000514022

unitedkingdom@bitrialsupport.com

Freeman Hospital

Newcastle Upon Tyne, United Kingdom, NE7 7DN

8000514022

unitedkingdom@bitrialsupport.com

Pipeline compound(s) are under pre-clinical and/or clinical investigation and have not been approved by regulatory authorities for commercial use in patients. Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.